WuXi will offer end-to-end support for the IMB1001 project. Credit: Lucas Vasques on Unsplash.

IMIDomics and WuXi Biologics have signed an agreement to advance the development and manufacturing of the humanised antibody IMB1001 for immune-mediated inflammatory diseases (IMIDs).

IMB1001 has been designed to target the transmembrane glycoprotein CD226.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the deal, WuXi will be responsible for delivering comprehensive chemistry manufacturing controls (CMC) development and current good manufacturing practice (cGMP) manufacturing services for the humanised antibody.

Leveraging its advanced facilities, technology and scientific team, WuXi will offer end-to-end support for the IMB1001 project.

It will be involved in analytical method establishment, process development, services related to CMC and cGMP manufacturing to be in line with regulatory standards.

IMIDomics used its technology and data sets to detect CD226 that is significantly upregulated during an inflammatory immune response.

IMB1001 can downregulate the pro-inflammatory cytokines production by blocking CD226 signalling.

The specific mechanism of action linked to the antibody has potentially wider applicability across several diseases.

IMIDomics leverages its multidimensional, integrated and data-driven platform, Discovery Engine, for identifying the underlying mechanisms of IMIDs.

IMIDomics chief development officer Daniel Perez said: “WuXi Biologics’ track record of excellence and expertise in biologics research, development and manufacturing aligns perfectly with our vision to bring transformative biologics therapies to IMID patients in need.

“This collaboration represents a significant milestone for IMIDomics as we advance IMB1001 towards clinical development.”

Last month, IMIDomics signed an exclusive agreement to license TNAX Biopharma’s IMB1001.

Under the deal, IMIDomics obtained global rights for the development, production, marketing and sub-licensing of IMB1001 from TNAX.